Royalty Pharma plc
http://www.royaltypharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Royalty Pharma plc
Teva Gets Investment From Royalty On Olanzapine LAI
Teva has announced a new investment from Royalty Pharma in its long-acting injectable formulation of olanzapine that is being developed for the US market with partner MedinCell.
Finance Watch: CARGO Gets A Lukewarm Reception After Stock Market Debut
Public Company Edition: CARGO Therapeutics grossed $281.3m, giving it the fifth-largest biopharma IPO this year. Also, Alkermes completed its cancer business spinout as Mural Oncology, which launched with $275m, and Xencor sold Ultomiris and Monjuvi royalties for $215m.
Vertex Gears Up For Major Milestones, Starting With Sickle Cell Launch And Pain Drug Readout
Having long attracted investors thanks to its promising pipeline, the moment of truth approaches for Vertex’s sickle cell gene therapy exo-cel, and VX-548, which has potential to transform acute and chronic pain treatment.
Stock Watch: Oncology Heritage Impedes Roche's Growth
Once a cancer drug powerhouse, Roche’s newer oncology launches were not taking up the slack caused by biosimilar competition to its former blockbusters. Something else was required.
Company Information
- Industry
- Miscellaneous
- Other Names / Subsidiaries
-
- Cypress Bioscience, Inc. (Cellatope Corporation
- Proprius Pharmaceuticals, Inc.)
- Ramius LLC
- Royalty Pharma AG
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice